Login / Signup

Supra-physiological doses of anabolic androgenic steroids impact erythropoietin and blood parameters.

Carmel E HeilandYasmin SchickelMikael LehtihetAnnica BörjessonLena Ekström
Published in: Drug testing and analysis (2023)
Hematological parameters and erythropoiesis are known to be influenced by anabolic androgenic steroid (AAS) use. However, little is known in relation to supra-physiological doses of AAS. Therefore, the aim of this study was to evaluate the effect of supra-physiological doses of AAS on serum and urinary erythropoietin (EPO), and blood parameters, from self-reported AAS users. Serum EPO levels were higher in testosterone positive AAS users (11.83 mIU/mL ± 4.19) than non-positive (6.60 mIU/mL ±2.70, p=0.03), while no differences in urinary EPO levels were noted. There were positive correlations between serum EPO and testosterone levels (rs=0.46, p=0.01) and reticulocyte percentage (rs=0.43, p=0.02). Individuals with AAS-induced hypogonadism (ASIH; luteinizing hormone levels <1.4 IU/L) had approximately 75 % higher serum EPO (p<0.05) and 140 % higher high fluorescence reticulocyte fractions (p<0.001), as well as other affected hematological parameters, compared to non-ASIH individuals. The results extend the knowledge of how endocrine and hematological biomarkers are affected by AAS doping.
Keyphrases
  • replacement therapy
  • healthcare
  • diabetic rats